Upgrade to SI Premium - Free Trial

Insys Therapeutics (INSY) Receives CRL from FDA on Buprenorphine NDA

July 27, 2018 12:51 PM
INSYS Therapeutics, Inc. (NASDAQ: INSY) announced that today it received a Complete Response Letter (CRL) from the U.S. Food and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA

Next Articles